Fatty Liver Disease Clinical Trials in Beijing, Beijing Municipality
8 recruitingBeijing, Beijing Municipality, China
Showing 1–8 of 8 trials
Recruiting
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease
FibrosisNonalcoholic SteatohepatitisNonalcoholic Fatty Liver Disease+1 more
Peking Union Medical College Hospital2,000 enrolled1 locationNCT05330923
Recruiting
Not Applicable
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss
Metabolic SyndromeNonalcoholic Fatty Liver DiseaseOverweight and/or Obesity+1 more
Liu Yan216 enrolled2 locationsNCT07237750
Recruiting
Phase 2
A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )
NAFLD - Non-Alcoholic Fatty Liver Disease
Hinova Pharmaceuticals Inc.80 enrolled2 locationsNCT07308548
Recruiting
Phase 1
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
NASH - Nonalcoholic SteatohepatitisNAFLD - Non-Alcoholic Fatty Liver Disease
Tasly Biopharmaceuticals Co., Ltd.32 enrolled5 locationsNCT07128797
Recruiting
Digital Early Warning System for Acute Lung Injury in Liver Surgery
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)Acute Lung Injury(ALI)Liver Cirrhosis+4 more
Beijing Tsinghua Chang Gung Hospital4,000 enrolled1 locationNCT07070362
Recruiting
Phase 3
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
OverweightMetabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Innovent Biologics (Suzhou) Co. Ltd.470 enrolled1 locationNCT06884293
Recruiting
LivQ-box® Parameters in the Diagnosis of Liver Inflammation
Fatty Liver DiseaseLiver Inflammation
Wuxi Hisky Medical Technology Co Ltd365 enrolled1 locationNCT06802731
Recruiting
Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal
Non-Alcoholic Fatty Liver Disease
Beijing Municipal Administration of Hospitals50 enrolled1 locationNCT06707129